Preoperative Combination Therapy with Camrelizumab, Paclitaxel, and Nedaplatin for Unresectable Advanced Esophageal Squamous Cell Carcinoma: Results from a Phase 2 Trial
By
Jinhong Zhu
Jinfeng Zhang
Xiaodong Ling
Changhong Wang
Yingnan Yang
Yangzhong Xin
Hao Jiang
Hao Liang
Luquan Zhang
Xionghai Qin
Jingle Lei
Chengyuan Fang
Xinxin Yang
Yuning Wang
Wei Meng
Xiaoyuan Wang
Hongxue Meng
Jianqun Ma
December 28, 2025
Clinical Scorecard: Preoperative Combination Therapy with Camrelizumab, Paclitaxel, and Nedaplatin for Unresectable Advanced Esophageal Squamous Cell Carcinoma: Results from a Phase 2 Trial
At a Glance
Category Detail
Condition Unresectable Advanced Esophageal Squamous Cell Carcinoma (ESCC) Key Mechanisms Combination of PD-1 inhibitor (camrelizumab) with chemotherapy (paclitaxel and nedaplatin) to facilitate conversion to surgical resection. Target Population Patients aged 18-70 with unresectable locally advanced/advanced ESCC (stage T2-4, N0-3, M0/M1). Care Setting Single-arm, prospective phase II clinical trial conducted at Harbin Medical University Cancer Hospital, China.
Key Highlights
Camrelizumab combined with chemotherapy shows potential as conversion therapy for unresectable ESCC. Induction therapy regimen includes camrelizumab (200 mg), paclitaxel (155 mg/m2), and nedaplatin (80 mg/m2) every 3 weeks. Efficacy evaluation based on RECIST 1.1 criteria to determine eligibility for surgical resection after every 2 cycles. Guideline-Based Recommendations
Diagnosis
Histologically proven locally advanced/advanced ESCC with specific unresectability criteria. Management
Preoperative combination therapy with camrelizumab, paclitaxel, and nedaplatin as a conversion strategy. Monitoring & Follow-up
Regular efficacy evaluations after every 2 cycles of therapy to assess operability. Risks
Potential serious adverse reactions necessitating modifications to the chemotherapy regimen. Patient & Prescribing Data
Patients with unresectable locally advanced/advanced ESCC, aged 18-70.
Combination therapy aims to enhance pathological complete response and facilitate surgical resection.
Clinical Best Practices
Adhere to eligibility criteria including ECOG performance status and organ function. Conduct thorough monitoring for adverse reactions during treatment cycles. References
